Scientists resurrect 160-million-year-old proteins to combat antibiotic resistance

In a laboratory at the University of Oregon, researchers have done something that sounds like science fiction: they have brought back to life proteins that last walked the Earth during the age of dinosaurs. These ancient molecules, reconstructed from genetic blueprints stretching back 160 million years, carry a property that modern medicine desperately needs—the ability to kill bacteria that have learned to shrug off our strongest antibiotics.

The work centers on lactoferrin, an immune protein that exists in nearly every fluid the human body produces except blood: breast milk, tears, saliva, mucus. Its original job was simple and elegant—to starve bacteria by locking away iron, an element pathogens need to survive. But somewhere in the deep past, lactoferrin evolved something more aggressive: an antimicrobial peptide, a short chain of amino acids that punctures holes in bacterial cell membranes, rupturing them from the inside. The question that drove Matt Barber and his team was when this lethal ability first appeared, and whether studying its evolution might teach us something useful about fighting infections today.

To answer that question, Titas Sil, a doctoral student in Barber's lab, did something methodical and strange. She compared the genetic sequences of lactoferrin in living animals—humans, cows, and others—and then worked backward through evolutionary time, using statistical inference to reconstruct what the ancestral versions of this protein must have looked like. The technique, called ancestral sequence reconstruction, allowed her to predict the most likely genetic code of lactoferrin as it existed millions of years ago. She synthesized these predicted genes and regenerated the ancient proteins in laboratory cells. Then she tested them.

What she found was unexpected. When she exposed bacteria to the oldest resurrected peptides—those from the earliest placental mammals—the pathogens could repair the damage and survive. But as she moved forward through evolutionary time, testing peptides from more recent ancestors, the antimicrobial activity grew stronger. Some versions from just a few million years ago outperformed the modern human version. The difference came down to a single mutation, a tiny change in the protein's structure that made it far more lethal. One small alteration, accumulated over millions of years of evolution, had transformed a moderately effective weapon into a superior one.

Barber describes evolution as a billions-year-old experiment, and in this case, the results are clear: nature had already solved the problem of how to kill resistant bacteria. The challenge now is understanding why. If scientists can decode the logic behind these ancient improvements, they might be able to design new treatments that pathogens cannot easily overcome. Clinical trials have already tested derivatives of human lactoferrin peptides, but Sil's work suggests that researchers don't need to invent something entirely new—they can learn from what evolution already perfected.

There is a significant caveat. Antimicrobial peptides are structurally fragile compared to conventional antibiotics. They break down quickly in the body, making them difficult to use as drugs. Barber and Sil are careful not to promise a quick fix. Drug development, they say, is likely years away. But the deeper insight matters more than the timeline. Bacteria will eventually evolve resistance to these peptides just as they have to antibiotics. The difference is that by understanding how resistance emerges, scientists might be able to anticipate it—designing combination treatments that stay ahead of the pathogen's adaptations rather than always playing catch-up. The ancient proteins are not a solution in themselves. They are a map, drawn by evolution, showing where solutions might be found.